143 results on '"Ferté C"'
Search Results
2. Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology
3. Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor
4. Treatment of Medulloblastoma in adults
5. LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
6. 1837P Assessing care complexity in remote patient monitoring (RPM): A cohort study of 2434 cancer patients across 50 sites in France and Belgium
7. 1836P Patient-reported health behaviors (PRHB) among 1850 patients enrolled in a remote patient monitoring (RPM) pathway
8. 595P Adoption of remote patient monitoring in gastrointestinal oncology: A real-world experience from 1822 patients across 47 centers in France and Belgium
9. Congrès Targeted Anticancer Therapies — TAT 2015
10. Ciblage pharmacologique de Mdm2 : bases biologiques et perspectives de radiosensibilisation
11. Chimiothérapie des métastases d’origine colorectale jamais résécables : stratégie multiligne, thérapies ciblées
12. Impact of centralization on aCGH-based genomic profiles for precision medicine in oncology
13. Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma
14. 326 (PB106) - Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor
15. EXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors
16. EP-1993: Evaluation of the pertinence of CT-based radiomics shape features with 3D printed phantoms
17. EXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors
18. Modern Miracles Of Healing
19. Referendum Report Of Council
20. The Indian Subordinate Medical Department
21. Molecular profile characterization and impact on clinical outcome in metastatic NSCLC patients enrolled in MOSCATO 01 trial
22. Precision medicine for patients with advanced biliary tract cancers: Updated results from the prospective MOSCATO trial
23. MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with Docetaxel, Cisplatin and 5-FU (DCF) in induction for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
24. A novel radiomic based imaging tool to monitor tumor lymphocyte infiltration and outcome of patients treated by anti-PD-1/PD-L1
25. A step towards the harmonization of clinical trials inform consent forms
26. 439P - Prospective validation of prognostic scores to improve patient selection for immuno-oncology trials
27. 182TiP - EXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors
28. Preliminary Results From a Phase 2 Trial of Tipifarnib in HRAS-Mutant Head and Neck Squamous Cell Carcinomas
29. 63P - EXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors
30. OC-014: Molecular screening for cancer treatment optimization in head and neck cancer (MOSCATO 01)
31. MA 10.11 Hyperprogressive Disease (HPD) Is Frequent in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Treated with Anti PD1/PD-L1 Agents (IO)
32. E4 - Molecular profile characterization and impact on clinical outcome in metastatic NSCLC patients enrolled in MOSCATO 01 trial
33. Predictive and Prognostic Value of CT Based Radiomics Signature in Head and Neck Squamous Cell Carcinoma Patients Treated With Concurrent Chemoradiation Therapy or Bioradiation Therapy and Its Added Value to Human Papillomavirus Status
34. 1632PD - A novel radiomic based imaging tool to monitor tumor lymphocyte infiltration and outcome of patients treated by anti-PD-1/PD-L1
35. 1109TiP - MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with Docetaxel, Cisplatin and 5-FU (DCF) in induction for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
36. 726P - Precision medicine for patients with advanced biliary tract cancers: Updated results from the prospective MOSCATO trial
37. Chemotherapy for previously unresectable colorectal metastases: Multi-line strategies and targeted therapies
38. 1073P - Is anti-PD-1/PD-L1 immunotherapy sensitizing for conventional cancer therapies?
39. 1066P - Rapid and objective CT-scan prognostic scoring identifies patients with long-term clinical benefit on phase I trials
40. 983P - An advanced tumor shape radiomic signature predicts recurrence of locally advanced (LA) HNSCC patients (pts)
41. 971P - High incidence of cetuximab-related infusion reactions in head and neck cancer pts (real life data)
42. Équipoise clinique et études cliniques randomisées en cancérologie
43. Is the maximal tolerated dose still the best primary endpoint? Analysis of 288 dose-seeking phase I trials
44. Determinants of accrual period of time in dose escalating phase I trials
45. Facteurs pronostiques et prédictifs des sarcomes des tissus mous : application concrète de la recherche translationnelle
46. 1186P - A Novel Gene Expression Signature that Robustly Predicts the Outcome of Patients Diagnosed with Stage 1 Nsclc
47. Molecular circuits of solid tumors: prognostic and predictive tools for bedside use.
48. État des lieux du DES de gynécologie médicale dans la région Nord-Pas-de-Calais
49. 7114 Interstitial pneumonitis during RAD-001 treatment: incidence by blinded radiological analysis
50. 1237 Is it ethical to enrol patients with advanced solid tumor in first line therapy in Phase 1 trials?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.